New studies report trial results of thalidomide in a variety of cancers and metabolic disorders
Thalidomide demonstrates potential activity in multiple myeloma, primary amyloidosis, metastatic colorectal cancer, and acute myeloid leukemia, with notable improvements in patient survival rates and side effects observed.